血液透析患者潜伏结核一个月每日利福喷丁治疗的药代动力学与耐受性
本研究在11例依赖透析的潜伏结核感染患者中开展24小时多剂药代动力学研究,评估每日利福喷丁450-600mg联合异烟肼300mg治疗4周的药代动力学与耐受性。结果显示利福喷丁中位Cmax为11.4 µg/mL,中位AUC0-24为177 µg·h/mL,暴露低于非透析历史队列,提示需更大规模研究优化该人群剂量。
要点
- 透析患者利福喷丁暴露(Cmax 11.4 µg/mL,AUC0-24 177 µg·h/mL)低于非透析人群。
- 11例中仅69%完成治疗,5例因不良事件或移植停药。
- 需更大规模研究以优化透析患者利福喷丁剂量。
核心结论
- 透析患者利福喷丁暴露低于非透析历史队列,需更大规模研究优化剂量。
研究设计与样本
- 24小时多剂药代动力学研究,纳入11例依赖透析的潜伏结核感染患者。
- 每日利福喷丁450-600 mg联合异烟肼300 mg治疗4周,第14天采8个时间点血样。
主要发现
- 11例(69%)完成治疗,5例因不良事件或移植停药。
- 中位Cmax为11.4 µg/mL(IQR 8.7-13.7),中位AUC0-24为177 µg·h/mL(IQR 134-206)。
- 平均利福喷丁剂量为9.9 ± 1.6 mg/kg,参与者63%男性,平均年龄49岁。
临床怎么用
- 透析患者使用每日利福喷丁联合异烟肼方案时,应关注暴露可能偏低及耐受性问题。
局限性
- 样本量小(11例),且药代动力学参数与非透析历史队列比较而非同期对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A one-month regimen of daily isoniazid plus rifapentine (1HP) is endorsed by WHO for latent tuberculosis infection (LTBI), showing efficacy and safety in people with human immunodeficiency virus (HIV). However, the pharmacokinetics (PK) of rifapentine in end-stage renal disease (ESRD) patients on dialysis remain unknown. METHODS: We conducted a 24-hour multiple-dose PK study of daily rifapentine in 11 dialysis-dependent patients with LTBI. Participants received rifapentine 450-600 mg plus isoniazid 300 mg daily for 4 weeks. Plasma samples were collected on day 14 at eight time points: pre-dose and 1, 2, 4, 6, 8, 12 and 24 hours post-dose. Rifapentine concentrations were measured using validated HPLC. PK parameters were compared with historical cohort from non-dialysed populations. RESULTS: Participants (63% male, mean age 49) received a mean rifapentine dose of 9.9 ± 1.6 mg/kg. Eleven (69%) completed treatment; five discontinued due to adverse events or transplantation. Median maximum concentration (Cmax) was 11.4 µg/mL (IQR, 8.7-13.7); median AUC0-24 was 177 µg·h/mL (IQR, 134-206). CONCLUSIONS: Rifapentine exposure in dialysis patients was lower than in non-dialysed historical cohorts, highlighting the need for larger studies to refine dosing in this population.
引用
- Ueaphongsukkit T, Udomkarnjananun S, Vanichanan J, et al. Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients. J Antimicrob Chemother. 2026. PMID: 41400843. doi:10.1093/jac/dkaf439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。